APR 19, 2020 3:35 PM PDT

FDA Approves New Drug for Breast Cancer

WRITTEN BY: Annie Lennon

 

The US Food and Drug Administration has approved a new drug, known as tucatinib or Tuksya, as a treatment for advanced forms of breast cancer. To be used alongside chemotherapy, it has been approved for cancer that cannot be removed by surgery, and that have spread to other parts of the body including the brain. 

In particular, the drug works against HER2-positive breast cancer- when the body has an excessive amount of a cancer-growing protein known as human epidermal growth factor receptor 2 (HER2). Responsible for around 1 in 5 cases of breast cancer, around 25% of women with the condition also develop brain metastases. 

The FDA approved Tuksya based on results from a controlled clinical trial examining its effects on 612 patients with treatment-resistant HER-2 positive breast cancer. In the end, the researchers found that patients who received the drug alongside chemotherapy and drugs trastuzumab and capecitabine had a progression-free survival (time in which the patient lives with the disease but it does not get worse) of 7.8 months compared to the 5.6 months of those on a placebo. Meanwhile, the overall survival and progression-free survival rate of those on the drug was 21.9 months as opposed to 17.4 months for those on the placebo. 

The researchers also noted that common side effects of the drug are diarrhea, palmar-plantar erythrodysesthesia (burning or tingling discomfort in the hands and feet), nausea, liver damage, decreased appetite and anemia among others. Meanwhile, they noted that serious side effects included severe diarrhea, acute kidney injury and death. 

"We recognize that patients with cancer constitute a vulnerable population at risk of contracting the coronavirus disease," says Dr. Richard Pazdur, director of the FDA’s Oncology Center of Excellence. "In this critical time, we remain steadfast in our commitment to patients with cancer and doing everything we can to expedite oncology product development. Tukysa was approved four months prior to the FDA goal date, providing an example of this commitment and showing how our regular work in reviewing treatments for patients with cancer is moving forward without delay."



Sources: FDA, CNN

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
SEP 27, 2020
Cell & Molecular Biology
How Spiders May Open a Path to IBS Treatment
SEP 27, 2020
How Spiders May Open a Path to IBS Treatment
Irritable bowel syndrome (IBS) is term that describes a gut disorder that causes abdominal pain, cramping, diarrhea or c ...
OCT 16, 2020
Drug Discovery & Development
FDA Warns Against NSAIDs After Week 20 of Pregnancy
OCT 16, 2020
FDA Warns Against NSAIDs After Week 20 of Pregnancy
The US Food and Drug Administration (FDA) has warned against using nonsteroidal anti-inflammatory drugs (NSAIDs) from 20 ...
NOV 11, 2020
Cancer
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
NOV 11, 2020
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
Amongst the most common targets of anti-cancer drugs are small regulatory molecules called cyclin-dependent kinases (CDK ...
NOV 17, 2020
Immunology
6 Injections a Year Prevent HIV Infections
NOV 17, 2020
6 Injections a Year Prevent HIV Infections
Last year, around 1.7 million people became infected with HIV, with around half of these being women. Encouraging result ...
NOV 17, 2020
Drug Discovery & Development
Antibiotics Before Age 2 Linked to Childhood Health Conditions
NOV 17, 2020
Antibiotics Before Age 2 Linked to Childhood Health Conditions
Researchers from Mayo Clinic have found a link between children aged two and under taking antibiotics and an increased r ...
DEC 01, 2020
Drug Discovery & Development
Breakthrough Drug Reduces Inflammation and Pain in Arthritis
DEC 01, 2020
Breakthrough Drug Reduces Inflammation and Pain in Arthritis
Researchers from the Universities of Oxford and Birmingham in the UK have found that otilimab can reduce infla ...
Loading Comments...